A detailed history of Huntington National Bank transactions in Castle Biosciences Inc stock. As of the latest transaction made, Huntington National Bank holds 1 shares of CSTL stock, worth $27. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 1 -0.0%
Holding current value
$27
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 07, 2024

SELL
$12.19 - $22.43 $4,424 - $8,142
-363 Reduced 99.73%
1 $0
Q3 2023

Nov 08, 2023

BUY
$13.28 - $20.3 $79 - $121
6 Added 1.68%
364 $6,000
Q2 2023

Aug 11, 2023

SELL
$11.66 - $26.0 $291 - $650
-25 Reduced 6.53%
358 $4,000
Q1 2023

May 10, 2023

BUY
$19.47 - $28.49 $253 - $370
13 Added 3.51%
383 $8,000
Q4 2022

Feb 09, 2023

BUY
$18.08 - $30.0 $1,392 - $2,310
77 Added 26.28%
370 $8,000
Q2 2022

Aug 09, 2022

BUY
$16.0 - $45.99 $4,016 - $11,543
251 Added 597.62%
293 $6,000
Q4 2021

Jan 21, 2022

BUY
$39.06 - $67.58 $1,640 - $2,838
42 New
42 $2,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $733M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.